Denovo Biopharma LLC Announces Multiple Presentations at Major Conferences
Denovo’s Licenses DB102 (Enzastaurin) for Rare Genetic Pediatric Onset Disorders to Aytu BioPharma
Denovo Biopharma Acquires a Novel Late-Stage Oncology Drug and Expands into Protein Therapeutics
2020/06 Denovo closes $83.5M series C round to support phase III trials of enzastaurin
2018/10 Denovo Biopharma to Participate at Morgan Stanley 17th Annual Asia Pacific Summit
2018/05 Denovo Biopharma to Participate in Jefferies 2018 Global Healthcare Conference
2018/05 Denovo Biopharma to Participate at Morgan Stanley 4th Annual China Summit
2018/01 San Diego's Denovo Biopharma Opens Doors to New R&D Center, Names New CMO and CFO
Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development. Our platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology.